Market Data 
Markets
Replies to post #221511 on Biotech Values
2. GE Healthcare
GE Healthcare, a business unit of General Electric Company, provides transformational medical technologies and services, as well as consulting services. With headquarters in Buckinghamshire, UK, it carries out the design, development, manufacture and distribution of medical systems in the field of medical imaging and information technologies, medical diagnostics, patient monitoring, drug discovery, and biopharmaceutical manufacturing technologies.
GE Healthcare also provides services, such as performance improvement and solutions services, computerised data management, and remote diagnostic and repair services of medical equipment manufactured by the company and others.
GE Healthcare’s products are used in cardiology; neurology; emergency medicine; oncology; woman’s health; ear, nose and throat (ENT); musculoskeletal; emergency care; radiology; paediatrics; urology and in the obstetrics/gynaecology areas. The company recorded revenue of $18.1 billion during the fiscal year ended December 2011.
The company’s business is divided chiefly into five segments: surgery, healthcare systems, life sciences, medical diagnostics and healthcare IT.
The medical diagnostics segment is engaged in the research, manufacture and marketing of innovative imaging agents, which are used in medical scanning procedures to highlight organs, tissues and functions inside the human body. These agents help physicians in the early detection, diagnosis and management of diseases. The company’s diagnostic imaging products include ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), mammography, molecular imaging, nuclear medicine, positron emission tomography (PET), radiopharmacy, pre-clinical imaging, radiography and radiography, and fluoroscopy systems.
In August 2012, the company received CE marking for its Discovery IGS 730, interventional X-ray system. It has introduced the Optima NM/CT 640 – the latest addition to its Nuclear Medicine 600 series with a new performance SPECT/CT system.
10/20/18 12:30 AM
Deep patent pool.
The development and protection of intellectual property ("IP") in thermoacoustic clinical applications is a key area of focus for ENDRA. To further that goal, the company currently has two patent agents embedded within the applied science team, working to define and secure IP to support ENDRA's innovations. As of today, ENDRA's IP portfolio totals 37 patents and patent applications that are in preparation, filed, issued or licensed, encompassing a range of device and method-focused IP in targeted global markets.
Other indications are also planned.
Currently, there are two commercially available preclinical photoacoustic im- aging systems as shown in Figure 3: Vevo LAZR (Fujifilm VisualSonics, Toronto, Canada; technology licensed from Seno Medical Instruments, San Antonio, Tex) and Nexus 128 (Endra, Ann Arbor, Mich; technology licensed from OptoSonics, Oriental, NC) (7,44– 49). Vevo LAZR uses high-frequency handheld transducers ranging from 9 to 55 MHz, which limits its use to small-animal imaging, while the Nexus 128 employs a 5-MHz hemispherical transducer array for photoacoustic CT which is potentially suitable for clinical imaging (however, currently not cleared by FDA for human use).
AI
